文献速递慢性肾脏病肾血管病与高血压

SGLT2抑制剂用于2型糖尿病合并CKD与心血管疾病:NKF科学研讨会报告

SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.
PubMed 文献 · Am J Kidney Dis · 2020-10-26

糖尿病是CKD最常见病因,CKD合并糖尿病患者主要死因为心血管疾病。SGLT2抑制剂在T2DM心血管安全性试验中一致降低肾脏复合终点及CVD事件风险,CREDENCE试验在特定CKD人群中确立卡格列净的肾脏与心血管获益。美国国家肾脏基金会召集80余位国际专家研讨,提出SGLT2抑制剂应尽可能用于T2DM患者以降低CKD与CVD风险,并需关注酮症酸中毒、生殖器真菌感染和容量不足等风险。

要点

  • SGLT2抑制剂可降低T2DM患者CKD与CVD风险,应尽可能使用。
  • CREDENCE试验在UACR>300mg/g且eGFR 30至<90的T2DM患者中确立卡格列净获益。
  • 需警惕正常血糖性酮症酸中毒、生殖器真菌感染和容量不足。

核心结论

  • SGLT2抑制剂应尽可能用于T2DM患者以降低CKD和CVD风险,使用应对齐临床试验入选标准。

研究设计与样本

  • 美国国家肾脏基金会召集80余位国际专家召开科学研讨会,讨论现有知识与未解问题并提出治疗方向。

主要发现

  • T2DM心血管安全性试验中观察到次要肾脏终点(白蛋白尿及血清肌酐翻倍或eGFR下降40%、肾衰竭或死亡的复合终点)风险一致降低,同时CVD事件减少。
  • CREDENCE试验在T2DM、尿白蛋白-肌酐比值>300mg/g且eGFR 30至<90mL/min/1.73m2的患者中确立卡格列净的肾脏与心血管获益。
  • SGLT2抑制剂改善肾小球血流动力学功能,并可能改善CKD和CVD发病机制中的其他局部和全身机制。

关键数值与推荐

  • CREDENCE入选标准:T2DM、尿白蛋白-肌酐比值>300mg/g、eGFR 30至<90mL/min/1.73m2。
  • SGLT2抑制剂使用应对齐临床试验入选标准。
  • 重要风险包括正常血糖性酮症酸中毒、生殖器真菌感染和容量不足。

临床怎么用

  • 对符合临床试验入选标准的T2DM患者,应尽可能使用SGLT2抑制剂以降低CKD和CVD风险。
  • 处方SGLT2抑制剂时需权衡获益与风险,并采取风险缓解策略。
  • 需要有效的实施策略以实现这类挽救生命药物的广泛使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Diabetes is the most frequent cause of chronic kidney disease (CKD), leading to nearly half of all cases of kidney failure requiring replacement therapy. The principal cause of death among patients with diabetes and CKD is cardiovascular disease (CVD). Sodium/glucose cotransporter 2 (SGLT2) inhibitors were developed to lower blood glucose levels by inhibiting glucose reabsorption in the proximal tubule. In clinical trials designed to demonstrate the CVD safety of SGLT2 inhibitors in type 2 diabetes mellitus (T2DM), consistent reductions in risks for secondary kidney disease end points (albuminuria and a composite of serum creatinine doubling or 40% estimated glomerular filtration rate decline, kidney failure, or death), along with reductions in CVD events, were observed. In patients with CKD, the kidney and CVD benefits of canagliflozin were established by the CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation) trial in patients with T2DM, urinary albumin-creatinine ratio>300mg/g, and estimated glomerular filtration rate of 30 to<90mL/min/1.73m2. To clarify and support the role of SGLT2 inhibitors for treatment of T2DM and CKD, the National Kidney Foundation convened a scientific workshop with an international panel of more than 80 experts. They discussed the current state of knowledge and unanswered questions to propose therapeutic approaches and delineate future research. SGLT2 inhibitors improve glomerular hemodynamic function and are thought to ameliorate other local and systemic mechanisms involved in the pathogenesis of CKD and CVD. SGLT2 inhibitors should be used when possible by people with T2DM to reduce risks for CKD and CVD in alignment with the clinical trial entry criteria. Important risks of SGLT2 inhibitors include euglycemic ketoacidosis, genital mycotic infections, and volume depletion. Careful consideration should be given to the balance of benefits and harms of SGLT2 inhibitors and risk mitigation strategies. Effective implementation strategies are needed to achieve widespread use of these life-saving medications.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Tuttle KR, Brosius FC, Cavender MA, et al. SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. Am J Kidney Dis. 2020. PMID: 33121838. doi:10.1053/j.ajkd.2020.08.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。